Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.

Taeang AraiMasanori AtsukawaAkihito TsubotaShigeru MikamiHiroki OnoTadamichi KawanoYuji YoshidaTomohide TanabeTomomi OkuboKorenobu HayamaAi Nakagawa-IwashitaNorio ItokawaChisa KondoKeiko KanekoNaoya EmotoMototsugu NagaoKyoko InagakiIzumi FukudaHitoshi SugiharaKatsuhiko Iwakiri

Published in: Therapeutic advances in endocrinology and metabolism (2021)

SGLT2-Is improved not only glycemic control but also liver fatty infiltration and fibrosis in patients with NAFLD and T2DM, suggesting their possible superiority to other OHAs concerning these effects.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
insulin resistance
liver fibrosis
electronic health record
big data
cardiovascular disease
adipose tissue
data analysis